Risk & Weakness
Qullamaggie: Parabolic (Short-Watch)
Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Market filter active: the list shows 8 hits from US
Kullamägi's third setup, the Parabolic (mostly SHORT): stocks act like rubber bands — when they're extremely overextended short-term, sharp snapbacks follow. Filter: ≥ 50% rise in the last month AND ≥ 3 ATR above the 21-EMA (climax/parabolic zone). The pullback's target zone is the 10-/20-day lines. NOT a buy signal — a watch list for reversal shorts (entry at opening-range lows / VWAP failed breakout, stop at the day's high). Less often, a stock qualifies for the Parabolic Long after a 50–60% sell-off.
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Funda Rating ≥ +10) are excluded.
🔔 Watch scanner
Terms in This Scanner Explained
(20)
- ADR (Average Daily Range)
- The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
- AI Classification
- Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
- Analysis (Full Company Analysis)
- If the Analysis column shows "Read," there is an in-depth Minnow Street company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
- ATR (Average True Range)
- The average daily range in dollars (instead of percent like the ADR), including gaps. Often used as a yardstick: "3 ATR above the 21-EMA" means the price has run three normal daily moves above its trend line - significantly extended.
- Avg/Yr 3Y (Average Annual Return)
- The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
- Breakout
- The price clears a level where it previously failed multiple times (top of a base, an old high) - ideally on clearly elevated volume. For many momentum strategies, the breakout is the actual buy signal.
- Earnings Date
- The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
- EMA (Exponential Moving Average)
- Like the simple moving average, but more recent prices carry more weight - the line follows price faster. The 21-day EMA is the standard short-term trend line for momentum traders.
- EPS (Earnings per Share)
- Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
- Free Cash Flow (FCF)
- Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
- Funda Rating (Fundamental Rating A+ to F)
- Our proprietary fundamental rating from -100 to +100 with a school-grade rank from A+ to F. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. A/A+ are the fundamentally strongest stocks in the universe.
- Long / Short
- Long = betting on rising prices (buying the stock). Short = betting on falling prices (selling borrowed shares to buy them back cheaper later). Our short scanners are warning or watch lists - not buy candidates.
- Market Capitalization (Mkt Cap)
- The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
- Net Margin
- How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
- Opening Range High/Low
- The high and low of the first minutes of trading (e.g., the first 5 or 60 minutes). Qullamaggie buys breakouts above the opening-range high and sets the stop at the day's low - an entry with clearly defined risk.
- Operating Cash Flow (OCF)
- The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
- Piotroski F-Score
- A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
- Sector & Industry
- Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
- Stage (Weinstein Stages 1-4)
- Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
- Stress RS (Strength on Stress Days)
- A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.
Hit List
Filter ▾
Rating (traffic light)
Stage
Funda Rating
Piotroski
Columns ▾
This scanner's columns
Extra columns
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Stress RS | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORKA Oruka Therapeutics, Inc. | 08/10 | +78 % | 79 7/22 | Stage 2 | D -36 | 1 of 9 | 5.4 | Biotechnology | – | — | — | Healthcare | 91.70 $ | +175.2 % | +188.0 % | +653.1 % | −4.8 % | +67.0 % | 98 | 42 | 7.5 % | 6.8 % | — | — | 0.0 | — | 10.8 | — | — | 0.0 | 0.0 % | — | 0.0 % | -27.3 % | -18.9 % | 0.00 | 96.5 % | +1,105.3 % | 0.0 % | 0.0 % | 34.0 | 89.1 % | 17.4 % | 1.0 (8) |
| DFTX Definium Therapeutics, Inc. | 07/30 | +332 % | — | Stage 2 | D -49 | 1 of 9 | 0.0 | Biotechnology | – | — | — | Healthcare | 42.80 $ | +170.2 % | +246.6 % | +534.0 % | −4.7 % | +24.7 % | 98 | 50 | 14.0 % | 8.8 % | 2.21 | — | 0.0 | — | 21.3 | — | — | 0.0 | 0.0 % | — | 0.0 % | -94.7 % | -35.7 % | — | 69.5 % | — | 0.0 % | 0.0 % | 1.4 | 65.6 % | 9.8 % | — |
| MBX MBX Biosciences, Inc. Common Stock | 08/06 | — | 69 6/22 | Stage 2 | D -33 | 3 of 9 | 2.3 | Biotechnology | – | — | — | Healthcare | 60.10 $ | +47.1 % | +67.7 % | +397.4 % | −4.1 % | +37.2 % | 97 | 42 | 8.5 % | 7.7 % | — | — | 0.0 | — | 5.5 | — | — | 0.0 | 0.0 % | — | 0.0 % | -25.7 % | -17.7 % | 0.00 | 96.7 % | — | 0.0 % | 0.0 % | 37.2 | 111.5 % | 16.8 % | 1.0 (5) |
| APGE Apogee Therapeutics, Inc. Common S | 08/10 | — | 68 6/22 | Stage 2 | D -30 | 4 of 9 | 10.0 | Biotechnology | – | — | — | Healthcare | 134.20 $ | +76.0 % | +69.8 % | +220.9 % | −0.4 % | -1.6 % | 96 | 42 | 6.7 % | 6.5 % | 0.33 | — | 0.0 | — | 7.9 | — | — | 0.0 | 0.0 % | — | 0.0 % | -28.5 % | -19.0 % | 0.01 | 97.1 % | — | 0.0 % | 0.0 % | 40.3 | 131.6 % | 22.0 % | 1.0 (9) |
| CLPT Clearpoint Neuro Inc | 08/11 | +61 % | 40 4/22 | Stage 3 | D -13 | 4 of 9 | 0.5 | Medical Devices | Neutral | — | — | Healthcare | 15.10 $ | +35.5 % | +34.1 % | +58.3 % | −40.3 % | +57.8 % | 90 | 42 | 11.6 % | 9.0 % | 1.24 | — | 12.1 | 13.4 | 28.7 | — | 0.61 | -7.1 | — | 62.3 % | -71.6 % | -149.7 % | -25.0 % | 3.38 | — | +17.8 % | 0.0 % | 0.0 % | -3.1 | 50.6 % | 17.0 % | — |
| WNC Wabash National Corporation | 07/24 | -16 % | 49 6/29 | Stage 2 | D -24 | 2 of 9 | 0.5 | Farm & Heavy Construction Ma | – | — | — | Industrials | 13.30 $ | +48.3 % | +56.9 % | +31.0 % | −0.6 % | +43.5 % | 78 | 97 | 9.6 % | 6.9 % | 1.42 | — | 8.6 | 0.4 | 1.8 | — | 0.73 | 2.0 | — | 2.8 % | -4.4 % | -17.8 % | -2.2 % | 1.66 | — | -20.8 % | 2.4 % | 6.3 % | 4.6 | 100.8 % | 9.4 % | — |
| EPC Edgewell Personal Care Co | 08/04 | -11 % | 3 0/16 | Stage 2 | D -31 | 4 of 9 | 1.2 | Household & Personal Product | – | — | — | Consumer Defensive | 28.60 $ | +56.0 % | +61.6 % | +13.7 % | −6.4 % | -3.9 % | 76 | 18 | 7.1 % | 5.8 % | 0.39 | — | 12.7 | 0.5 | — | 23.8 | 2.87 | 16.8 | 9.3 % | 41.0 % | -3.5 % | -0.7 % | 3.2 % | — | 41.0 % | -1.3 % | 2.2 % | 85.7 % | 5.9 | 122.0 % | 13.2 % | 1.6 (9) |
| RGNX Regenxbio Inc | 08/06 | -16 % | 15 2/22 | Stage 4 | D -47 | 1 of 9 | 0.5 | Biotechnology | – | — | — | Healthcare | 10.30 $ | -30.9 % | -18.2 % | +26.8 % | −36.8 % | +137.9 % | 46 | 42 | 13.1 % | 9.4 % | 0.90 | — | 0.0 | 5.9 | — | — | 0.26 | -3.4 | — | -196.6 % | 0.0 % | -196.4 % | -38.5 % | — | — | +104.5 % | 0.0 % | 0.0 % | -10.9 | 84.7 % | 19.3 % | — |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Kullamägi's third setup, the Parabolic (mostly SHORT): stocks act like rubber bands — when they're extremely overextended short-term, sharp snapbacks follow. Filter: ≥ 50% rise in the last month AND ≥ 3 ATR above the 21-EMA (climax/parabolic zone). The pullback's target zone is the 10-/20-day lines.
All scanners are recalculated daily across the entire stock universe — most recently on 21. July 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 8 stocks pass this scanner's criteria (as of 21. July 2026).
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Funda Rating ≥ +10) are excluded.
This scanner deliberately hunts for red flags — a hit is a finding, not a recommendation: like a smoke detector that beeps so you look in time. A hit is also not a bankruptcy verdict; most companies save themselves (say, through a capital raise, which dilutes existing shareholders). Portfolio owners use the list as an early-warning system, bargain hunters as an anti-shopping list, experienced traders as a watch list — it is never a buy or short recommendation.
Related scanners
- Altman Z: Distress Zone
- Below the 50- & 200-SMA
- Beneish M-Score
- Downward Momentum
- Going Concern (Distress Proxy)
- Insolvency Radar: Cash Running Low
- Kathy Donnelly: Liquid Movers Down
- Mike Webster: Overextended (Webby RSI)
- Near 52-Week Low
- Pradeep Bonde: $ Breakout Bearish
- Pradeep Bonde: 4% Breakout Bearish
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Thomas Insolvency Candidate
- Weakness Cluster
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.